Mini-allografting to complement treatment with Glivec (imatinib - formerly known as STI571) to eradicate minimal residual disease (MRD) in chronic myeloid leukaemia (CML) patients aged 65 years and under with matched sibling donors
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 24 Feb 2006 New trial record.